Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001683168-24-007517
Filing Date
2024-10-31
Accepted
2024-10-31 16:30:31
Documents
16
Period of Report
2024-12-11

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY xenetic_idef14a.htm   iXBRL DEF 14A 411296
2 GRAPHIC image_001.jpg GRAPHIC 666145
3 GRAPHIC image_002.jpg GRAPHIC 360825
  Complete submission text file 0001683168-24-007517.txt   3221403

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE xbio-20231231.xsd EX-101.SCH 4305
5 XBRL DEFINITION FILE xbio-20231231_def.xml EX-101.DEF 7027
6 XBRL LABEL FILE xbio-20231231_lab.xml EX-101.LAB 56367
7 XBRL PRESENTATION FILE xbio-20231231_pre.xml EX-101.PRE 42616
18 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_idef14a_htm.xml XML 75330
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37937 | Film No.: 241415690
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)